Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CARA
CUSIPN/A
Phone203-406-3700
Debt
Debt-to-Equity RatioN/A
Current Ratio11.47
Quick Ratio11.47
Price-To-Earnings
Trailing P/E Ratio-8.95
Forward P/E Ratio-7.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$910,000.00
Price / Sales597.94
Cash FlowN/A
Price / CashN/A
Book Value$2.66 per share
Price / Book6.26
Profitability
EPS (Most Recent Fiscal Year)($1.86)
Net Income$-58,120,000.00
Net MarginsN/A
Return on Equity-57.40%
Return on Assets-52.21%
Miscellaneous
Employees37
Outstanding Shares32,700,000
Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions
What is Cara Therapeutics' stock symbol?
Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."
How were Cara Therapeutics' earnings last quarter?
Cara Therapeutics Inc (NASDAQ:CARA) announced its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.04. View Cara Therapeutics' Earnings History.
What price target have analysts set for CARA?
12 brokers have issued twelve-month price objectives for Cara Therapeutics' shares. Their predictions range from $20.00 to $31.50. On average, they anticipate Cara Therapeutics' stock price to reach $25.2692 in the next year. View Analyst Ratings for Cara Therapeutics.
What are Wall Street analysts saying about Cara Therapeutics stock?
Here are some recent quotes from research analysts about Cara Therapeutics stock:
- 1. HC Wainwright analysts commented, "We view this as a clear positive for the company, as it brings in minimally- dilutive financing ($50M cash plus $20M equity investment at $17/ share), validates our view on Korsuva, and de-risks the U.S. commercial launch. Despite the headline ex-US deal, we’re more focused on the new U.S. arrangement here because we don’t yet include ex-US in our model until we get more clarity on the regulatory and reimbursement landscape (our valuation is all-U.S.), and we assume the U.S. was also the primary value driver here for Vifor Fresenius as well. Vifor Fresenius is a JV of Vifor (VIFN:SW) and Fresenius Medical Care AG (FMS; not covered). We believe Vifor Fresenius is the best possible commercial partner for Cara, with Fresenius itself owning nearly 40% of U.S. dialysis centers." (5/23/2018)
- 2. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (3/21/2018)
- 3. Needham & Company LLC analysts commented, "Cara announced outcome of planned CR845 Phase 2/3 post-surgical pain trial interim power assessment today. We spoke w/ mgmt for an update. No changes will be made to current randomization ratio across the 3 arms (1:1:1 placebo, 0.5 ug/kg, 1.0ug/kg), however target enrollment will be increased from 125/ arm to 150/ arm. Other pre-specified options were ending trial early due to low probability of success or shifting enrollment to one optimal dose. We view outcome favorably, noting that the two dose arms were evaluated independently by Data Monitoring Cmtee. Implication is that both low and high dose CR845 have potential for statistically significant effect in view of DMC. We had been concerned that low and possibly high dose evaluated in this trial may not be sufficiently high for efficacy. Mgmt guided for completing enrollment for final analysis by YE17. Separately, top-line results from CR845 Phase 2b trial in Osteoarthritis are expected later this month. We are favorably inclined based on encouraging trends in an 80-pt 2wk Phase 2a trial, but acknowledge risks tied to absence of placebo arm." (6/21/2017)
Who are some of Cara Therapeutics' key competitors?
Some companies that are related to Cara Therapeutics include Xencor (XNCR), Enanta Pharmaceuticals (ENTA), Global Blood Therapeutics (GBT), TESARO (TSRO), Heron Therapeutics (HRTX), Spectrum Pharmaceuticals (SPPI), Puma Biotechnology (PBYI), Endo International (ENDP), Insmed (INSM), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Corcept Therapeutics (CORT), Prestige Brands (PBH), Phibro Animal Health (PAHC) and Akorn (AKRX).
Who are Cara Therapeutics' key executives?
Cara Therapeutics' management team includes the folowing people:
- Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 54)
- Dr. Frédérique Menzaghi Ph.D., Sr. VP of R&D (Age 52)
- Dr. Joseph Stauffer D.O., M.B.A., Chief Medical Officer (Age 52)
- Dr. Michael E. Lewis Ph.D., Co-Founder and Chief Scientific Advisor (Age 66)
- Dr. Mani Mohindru, Chief Financial Officer (Age 46)
Has Cara Therapeutics been receiving favorable news coverage?
Media stories about CARA stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cara Therapeutics earned a daily sentiment score of 0.07 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.67 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Cara Therapeutics' major shareholders?
Cara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.61%), Nexthera Capital LP (1.07%), ETF Managers Group LLC (1.03%), JPMorgan Chase & Co. (1.00%), C WorldWide Group Holding A S (0.71%) and UBS Group AG (0.55%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.
Which institutional investors are selling Cara Therapeutics stock?
CARA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Tiverton Asset Management LLC, C WorldWide Group Holding A S, JPMorgan Chase & Co. and Stifel Financial Corp. Company insiders that have sold Cara Therapeutics company stock in the last year include Dean Slagel, Derek T Chalmers and Frederique PhD Menzaghi. View Insider Buying and Selling for Cara Therapeutics.
Which institutional investors are buying Cara Therapeutics stock?
CARA stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP, ETF Managers Group LLC, UBS Group AG, Wells Fargo & Company MN, LPL Financial LLC, DekaBank Deutsche Girozentrale, Commonwealth Equity Services LLC and Swiss National Bank. View Insider Buying and Selling for Cara Therapeutics.
How do I buy shares of Cara Therapeutics?
Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cara Therapeutics' stock price today?
One share of CARA stock can currently be purchased for approximately $16.64.
How big of a company is Cara Therapeutics?
Cara Therapeutics has a market capitalization of $553.61 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-58,120,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Cara Therapeutics employs 37 workers across the globe.
How can I contact Cara Therapeutics?
Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.
MarketBeat Community Rating for Cara Therapeutics (CARA)
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
